mProX™ Human VRK2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human VRK2 Stable Cell Line (S01YF-1023-PY128). Click the button above to contact us or submit your feedback about this product.
Taylor Miller (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Skyler Miller (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The depletion of VRK2 results in a slight inhibition of cell growth.
Cell proliferation experiments were conducted employing a real-time cell analyzer with 293T cells stably expressing VRK2 shRNA variants, specifically #02 and #07. The application of VRK2 shRNA (#02 and #07) effectively inhibited the intrinsic cell growth, yielding consistent outcomes across HeLa cell clones that carried VRK2 shRNA constructs.
Ref: Hirata, Noriyuki, et al. "Functional characterization of lysosomal interaction of Akt with VRK2." Oncogene 37.40 (2018): 5367-5386.
Pubmed: 29872222
DOI: 10.1038/s41388-018-0330-0
Research Highlights
Zhang, Jie. et al. "Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice." Experimental & molecular medicine, 2023.
This article is about a study that claims to have discovered a new driver of liver cancer metastasis and a potential therapeutic target. The study found that high expression of FBXL6 in hepatocytes activates a pathway involving VRK2, TKT, ROS, mTOR, PD-L1 and immune evasion. The study also showed that blocking TKT can inhibit this pathway and reduce liver cancer metastasis in mice. The study suggests that patients with high FBXL6 expression may benefit from targeting the TKT-ROS-mTOR-PD-L1/VRK2 axis.
Zhang, Jie. et al. "Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice." Experimental & molecular medicine, 2023.
Pubmed:
37783772
DOI:
10.1038/s12276-023-01116-8
You, Mingyao. et al. "The association between epilepsy and COVID-19: analysis based on Mendelian randomization and FUMA." Frontiers in neuroscience, 2023.
Numerous observational studies have demonstrated a significant comorbidity between COVID-19 and epilepsy. The focus of this study was to establish a conclusive causal relationship between these two conditions. The study aimed to confirm the connection between COVID-19 and epilepsy through comprehensive analysis and research.
You, Mingyao. et al. "The association between epilepsy and COVID-19: analysis based on Mendelian randomization and FUMA." Frontiers in neuroscience, 2023.
Pubmed:
37781245
DOI:
10.3389/fnins.2023.1235822
